Literature DB >> 18377892

Characterization of novel non-peptide thrombopoietin mimetics, their species specificity and the activation mechanism of the thrombopoietin receptor.

Noriko Yamane1, Yoshikazu Tanaka, Naoki Ohyabu, Shoji Yamane, Kazuhiko Maekawa, Jun Ishizaki, Ryuji Suzuki, Tsunetoshi Itoh, Hiroshi Takemoto.   

Abstract

A series of non-peptide small compounds discovered to be thrombopoietin receptor agonists showed species specificity to humans. Compound I could induce megakaryocyte lineage from human bone marrow cells, but not from mouse, guinea pig or cynomolgus monkey bone marrow cells. To elucidate the mechanism, we identified the pivotal amino acid residue for the receptor activation by compound I by taking advantage of its species specificity. The response of compound I to three human/mouse chimeric receptors indicated the importance of the transmembrane domain. Comparison of amino acid sequences of the transmembrane domain of the thrombopoietin receptor between human and three animal species led us to hypothesize that histidine 499 is necessary for the reactivity to the thrombopoietin mimetics. We verified the hypothesis using two mutant receptors: the human thrombopoietin receptor mutant His499Leu and the mouse thrombopoietin receptor mutant Leu490His. These results should be helpful for structure-activity relationship studies and conducting in vivo studies of thrombopoietin mimetics.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18377892     DOI: 10.1016/j.ejphar.2008.02.060

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

Review 1.  Thrombopoietin and platelet production in chronic immune thrombocytopenia.

Authors:  David J Kuter; Terry B Gernsheimer
Journal:  Hematol Oncol Clin North Am       Date:  2009-12       Impact factor: 3.722

Review 2.  Biology and chemistry of thrombopoietic agents.

Authors:  David J Kuter
Journal:  Semin Hematol       Date:  2010-07       Impact factor: 3.851

3.  Thrombopoietin receptor activation: transmembrane helix dimerization, rotation, and allosteric modulation.

Authors:  Erin E Matthews; Damien Thévenin; Julia M Rogers; Lisa Gotow; Paul D Lira; Lawrence A Reiter; William H Brissette; Donald M Engelman
Journal:  FASEB J       Date:  2011-03-14       Impact factor: 5.191

4.  Avatrombopag, an oral thrombopoietin receptor agonist: results of two double-blind, dose-rising, placebo-controlled Phase 1 studies.

Authors:  David J Kuter; Lee F Allen
Journal:  Br J Haematol       Date:  2018-09-11       Impact factor: 6.998

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.